메뉴 건너뛰기




Volumn 2, Issue 3, 2006, Pages 331-340

Anakinra in the treatment of rheumatic disease

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6 RECEPTOR ANTIBODY; LEFLUNOMIDE; METHIONINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEGSUNERCEPT; PLACEBO; RECEPTOR ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

EID: 33748512180     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.2.3.331     Document Type: Review
Times cited : (14)

References (96)
  • 1
    • 0035932519 scopus 로고    scopus 로고
    • Cytokine pathways and joint inflammation in rheumatoid arthritis
    • Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344(12), 907-916 (2001).
    • (2001) N. Engl. J. Med. , vol.344 , Issue.12 , pp. 907-916
    • Choy, E.H.1    Panayi, G.S.2
  • 2
    • 0023712236 scopus 로고
    • Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum
    • Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31(8), 1041-1045 (1988).
    • (1988) Arthritis Rheum. , vol.31 , Issue.8 , pp. 1041-1045
    • Saxne, T.1    Palladino Jr., M.A.2    Heinegard, D.3    Talal, N.4    Wollheim, F.A.5
  • 3
    • 0029085746 scopus 로고
    • Cytokines in rheumatoid arthritis
    • Houssiau FA. Cytokines in rheumatoid arthritis. Clin. Rheumatol. 14(Suppl. 2). 10-13 (1995).
    • (1995) Clin. Rheumatol. , vol.14 , Issue.SUPPL. 2 , pp. 10-13
    • Houssiau, F.A.1
  • 4
    • 0012786007 scopus 로고
    • Epidemiology
    • In: Management. Utsinger P, Zvaifler N, Ehrlich G (Ed.). JB Lippincott, Philadelphia, PA, USA
    • Mitchell D. Epidemiology. In: Rheumatoid Arthritis: Etiology, Diagnosis, Management. Utsinger P, Zvaifler N, Ehrlich G (Ed.). JB Lippincott, Philadelphia, PA, USA, 133-137 (1985).
    • (1985) Rheumatoid Arthritis: Etiology, Diagnosis , pp. 133-137
    • Mitchell, D.1
  • 5
    • 12444256001 scopus 로고
    • Multidisciplinary ambulatory care for the elderly arthritis patient
    • In: Moskowitz H, Haug M (Eds). Springer, New York, USA
    • Robinson H. Multidisciplinary ambulatory care for the elderly arthritis patient. In: Arthritis and the Elderly. Moskowitz H, Haug M (Eds). Springer, New York, USA, 146-149 (1986).
    • (1986) Arthritis and the Elderly , pp. 146-149
    • Robinson, H.1
  • 6
    • 0038011833 scopus 로고    scopus 로고
    • Evolving concepts of rheumatoid arthritis
    • Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 423(6937), 356-361 (2003).
    • (2003) Nature , vol.423 , Issue.6937 , pp. 356-361
    • Firestein, G.S.1
  • 7
    • 1442352158 scopus 로고    scopus 로고
    • Epidemiology and burden of illness of rheumatoid arthritis
    • Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 22(Suppl. 2), 1-12 (2004).
    • (2004) Pharmacoeconomics , vol.22 , Issue.SUPPL. 2 , pp. 1-12
    • Kvien, T.K.1
  • 8
    • 0018920615 scopus 로고
    • The epidemiology of rheumatoid arthritis in Rochester, Minnesota: A study of incidence, prevalence, and mortality
    • Linos A, Worthington JW, O'Fallon WM, Kurland LT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am. J. Epidemiol. 111(1), 87-98 (1980).
    • (1980) Am. J. Epidemiol. , vol.111 , Issue.1 , pp. 87-98
    • Linos, A.1    Worthington, J.W.2    O'Fallon, W.M.3    Kurland, L.T.4
  • 9
    • 16844371735 scopus 로고    scopus 로고
    • Classification and epidemiology
    • In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Eds). Elsevier Science, Phildelphia, PA, USA
    • MacGregor AJ, Silman AJ. Classification and epidemiology. In: Rheumatology. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Eds). Elsevier Science, Phildelphia, PA, USA, 757-763 (2003).
    • (2003) Rheumatology , pp. 757-763
    • MacGregor, A.J.1    Silman, A.J.2
  • 10
    • 0031968825 scopus 로고    scopus 로고
    • Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
    • Lawrence RC, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41(5), 778-799 (1998).
    • (1998) Arthritis Rheum. , vol.41 , Issue.5 , pp. 778-799
    • Lawrence, R.C.1    Helmick, C.G.2    Arnett, F.C.3
  • 11
    • 0023024826 scopus 로고
    • Occurrence of rheumatoid arthritis in a nationwide series of twins
    • Aho K, Koskenvuo M, Tuominen J, Kaprio J. Occurrence of rheumatoid arthritis in a nationwide series of twins. J. Rheumatol. 13(5), 899-902 (1986).
    • (1986) J. Rheumatol. , vol.13 , Issue.5 , pp. 899-902
    • Aho, K.1    Koskenvuo, M.2    Tuominen, J.3    Kaprio, J.4
  • 12
    • 0027375302 scopus 로고
    • Twin concordance rates for rheumatoid arthritis: Results from a nationwide study
    • Silman AJ, MacGregor AJ, Thomson W et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br. J. Rheumatol. 32(10), 903-907 (1993).
    • (1993) Br. J. Rheumatol. , vol.32 , Issue.10 , pp. 903-907
    • Silman, A.J.1    MacGregor, A.J.2    Thomson, W.3
  • 13
    • 0032746370 scopus 로고    scopus 로고
    • Socio-economic consequences of rheumatoid arthritis in the first years of the disease
    • Albers JM, Kuper HH, Van Riel PL et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 38(5), 423-430 (1999).
    • (1999) Rheumatology (Oxford) , vol.38 , Issue.5 , pp. 423-430
    • Albers, J.M.1    Kuper, H.H.2    Van Riel, P.L.3
  • 14
    • 0034123823 scopus 로고    scopus 로고
    • Direct and indirect costs of rheumatoid arthritis to an employer
    • Birnbaum HG, Barton M, Greenberg PE et al. Direct and indirect costs of rheumatoid arthritis to an employer. J. Occup. Environ. Med. 42(6), 588-596 (2000).
    • (2000) J. Occup. Environ. Med. , vol.42 , Issue.6 , pp. 588-596
    • Birnbaum, H.G.1    Barton, M.2    Greenberg, P.E.3
  • 15
    • 0142135697 scopus 로고    scopus 로고
    • Direct medical costs and their predictors in patients with rheumatoid arthritis: A three-year study of 7,527 patients
    • Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 48(10), 2750-2762 (2003).
    • (2003) Arthritis Rheum. , vol.48 , Issue.10 , pp. 2750-2762
    • Michaud, K.1    Messer, J.2    Choi, H.K.3    Wolfe, F.4
  • 16
    • 26944465819 scopus 로고    scopus 로고
    • Diagnosis and management of rheumatoid arthritis
    • Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am. Fam. Physician 72(6), 1037-1047 (2005).
    • (2005) Am. Fam. Physician , vol.72 , Issue.6 , pp. 1037-1047
    • Rindfleisch, J.A.1    Muller, D.2
  • 17
    • 0033001678 scopus 로고    scopus 로고
    • An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional decline
    • Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 42(6), 1209-1218 (1999).
    • (1999) Arthritis Rheum. , vol.42 , Issue.6 , pp. 1209-1218
    • Yelin, E.1    Wanke, L.A.2
  • 18
    • 6744245548 scopus 로고    scopus 로고
    • How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS)
    • Young A, Dixey J, Cox N et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 39(6), 603-611 (2000).
    • (2000) Rheumatology (Oxford) , vol.39 , Issue.6 , pp. 603-611
    • Young, A.1    Dixey, J.2    Cox, N.3
  • 19
    • 0036210887 scopus 로고    scopus 로고
    • Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS)
    • Young A, Dixey J, Kulinskaya E et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann. Rheum. Dis. 61(4), 335-340 (2002).
    • (2002) Ann. Rheum. Dis. , vol.61 , Issue.4 , pp. 335-340
    • Young, A.1    Dixey, J.2    Kulinskaya, E.3
  • 20
    • 32544439865 scopus 로고    scopus 로고
    • The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits
    • Ozminkowski RJ, Burton WN, Goetzel RZ, Maclean R, Wang S. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J. Occup. Environ. Med. 48(2), 135-148 (2006).
    • (2006) J. Occup. Environ. Med. , vol.48 , Issue.2 , pp. 135-148
    • Ozminkowski, R.J.1    Burton, W.N.2    Goetzel, R.Z.3    Maclean, R.4    Wang, S.5
  • 21
    • 20244372077 scopus 로고    scopus 로고
    • Therapeutic strategies for rheumatoid arthritis
    • O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med. 350(25), 2591-2602 (2004).
    • (2004) N. Engl. J. Med. , vol.350 , Issue.25 , pp. 2591-2602
    • O'Dell, J.R.1
  • 22
    • 31044442965 scopus 로고    scopus 로고
    • The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
    • Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26-37 (2006).
    • (2006) Arthritis Rheum. , vol.54 , Issue.1 , pp. 26-37
    • Breedveld, F.C.1    Weisman, M.H.2    Kavanaugh, A.F.3
  • 23
    • 10744223002 scopus 로고    scopus 로고
    • Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial
    • Klareskog L, van der Heijde DM, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004).
    • (2004) Lancet , vol.363 , Issue.9410 , pp. 675-681
    • Klareskog, L.1    van der Heijde, D.M.2    de Jager, J.P.3
  • 24
    • 8444239359 scopus 로고    scopus 로고
    • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
    • St Clair EW, van der Heijde DM, Smolen J et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50(11), 3432-3443 (2004).
    • (2004) Arthritis Rheum. , vol.50 , Issue.11 , pp. 3432-3443
    • St Clair, E.W.1    van der Heijde, D.M.2    Smolen, J.3
  • 25
    • 0034735827 scopus 로고    scopus 로고
    • A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
    • Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343(22), 1586-1593 (2000).
    • (2000) N. Engl. J. Med. , vol.343 , Issue.22 , pp. 1586-1593
    • Bathon, J.M.1    Martin, R.W.2    Fleischmann, R.M.3
  • 26
    • 27744514865 scopus 로고    scopus 로고
    • Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
    • Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52(11), 3381-3390 (2005).
    • (2005) Arthritis Rheum. , vol.52 , Issue.11 , pp. 3381-3390
    • Goekoop-Ruiterman, Y.P.1    de Vries-Bouwstra, J.K.2    Allaart, C.F.3
  • 27
    • 3242677099 scopus 로고    scopus 로고
    • Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial
    • Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430), 263-269 (2004).
    • (2004) Lancet , vol.364 , Issue.9430 , pp. 263-269
    • Grigor, C.1    Capell, H.2    Stirling, A.3
  • 28
    • 33748518459 scopus 로고    scopus 로고
    • Adalimumab (HUMIRA®) plus MTX prevents nearly all severe radiographic progression observed with methotrexate monotherapy in early, aggressive rheumatoid arthritis
    • (Abstract 207)
    • van der Heijde DM, Landewe R, Keystone E, Van Riel PL, Sasso E, Perez J. Adalimumab (HUMIRA®) plus MTX prevents nearly all severe radiographic progression observed with methotrexate monotherapy in early, aggressive rheumatoid arthritis. Arthritis Rheum. 52(Suppl. 9), (2005) (Abstract 207).
    • (2005) Arthritis Rheum. , vol.52 , Issue.SUPPL. 9
    • van der Heijde, D.M.1    Landewe, R.2    Keystone, E.3    Van Riel, P.L.4    Sasso, E.5    Perez, J.6
  • 29
    • 33748504851 scopus 로고    scopus 로고
    • Three years of sustained halting of radiographic progression with combination etanercept and methotrexate: Results from the TEMPO Trial
    • (Abstract)
    • van der Heijde DM, Klareskog L, Wajdula J, Pedersen R, Fatenejad S. Three years of sustained halting of radiographic progression with combination etanercept and methotrexate: results from the TEMPO Trial. Arthritis Rheum. 52(Suppl. 9), L10-L14 (2005) (Abstract).
    • (2005) Arthritis Rheum. , vol.52 , Issue.SUPPL. 9
    • van der Heijde, D.M.1    Klareskog, L.2    Wajdula, J.3    Pedersen, R.4    Fatenejad, S.5
  • 30
    • 0030068817 scopus 로고    scopus 로고
    • Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria
    • van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, Van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 39(1), 34-40 1996).
    • (1996) Arthritis Rheum. , vol.39 , Issue.1 , pp. 34-40
    • van Gestel, A.M.1    Prevoo, M.L.2    van't Hof, M.A.3    van Rijswijk, M.H.4    van de Putte, L.B.5    Van Riel, P.L.6
  • 31
    • 0031715621 scopus 로고    scopus 로고
    • Validation of rheumatoid arthritis improvement criteria that include simplified joint counts
    • van Gestel AM, Haagsma CJ, Van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 41(10), 1845-1850 (1998).
    • (1998) Arthritis Rheum. , vol.41 , Issue.10 , pp. 1845-1850
    • van Gestel, A.M.1    Haagsma, C.J.2    Van Riel, P.L.3
  • 32
    • 33646597828 scopus 로고    scopus 로고
    • Poor remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept - Results from the nationwide Danish "DANBIO" database
    • Ostergaard M, Unkerskov J, Krough NS et al. Poor remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept - results from the nationwide Danish "DANBIO" database. Ann. Rheum. Dis. 64(Suppl. III), OP0011 (2005).
    • (2005) Ann. Rheum. Dis. , vol.64 , Issue.SUPPL. III
    • Ostergaard, M.1    Unkerskov, J.2    Krough, N.S.3
  • 33
    • 33344461104 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab in active RA patients who experienced an inadequate response to one or more anti-TNF-α therapies (REFLEX Study)
    • (Abstract 1839)
    • Cohen S, Greenwald M, Dougados M et al. Efficacy and safety of rituximab in active RA patients who experienced an inadequate response to one or more anti-TNF-α therapies (REFLEX Study). Arthritis Rheum. 52(Suppl. 9), (2005) (Abstract 1839).
    • (2005) Arthritis Rheum. , vol.52 , Issue.SUPPL. 9
    • Cohen, S.1    Greenwald, M.2    Dougados, M.3
  • 34
    • 24944498854 scopus 로고    scopus 로고
    • Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
    • Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353(11), 1114-1123 (2005).
    • (2005) N. Engl. J. Med. , vol.353 , Issue.11 , pp. 1114-1123
    • Genovese, M.C.1    Becker, J.C.2    Schiff, M.3
  • 35
    • 39549111980 scopus 로고    scopus 로고
    • Effectiveness of biologics and disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: Real-world outcomes from the RADIUS observational registry
    • (Abstract 1947)
    • Weaver A, Lautzenheiser RL, Schiff MH et al. Effectiveness of biologics and disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: real-world outcomes from the RADIUS observational registry. Arthritis Rheum. 52(Suppl. 9), (2005) (Abstract 1947).
    • (2005) Arthritis Rheum. , vol.52 , Issue.SUPPL. 9
    • Weaver, A.1    Lautzenheiser, R.L.2    Schiff, M.H.3
  • 36
    • 2342551979 scopus 로고    scopus 로고
    • Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
    • Genovese MC, Cohen S, Moreland L et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50(5), 1412-1419 (2004).
    • (2004) Arthritis Rheum. , vol.50 , Issue.5 , pp. 1412-1419
    • Genovese, M.C.1    Cohen, S.2    Moreland, L.3
  • 37
    • 27444447691 scopus 로고    scopus 로고
    • Safety of abatacept in patients with active rheumatoid arthritis receiving background non-biologic and biologic DMARDs: 1 year results of the ASSURE trial
    • [Op0012])
    • Weinblatt ME, Combe B, White A, Aranda R, Becker J, Keystone E. Safety of abatacept in patients with active rheumatoid arthritis receiving background non-biologic and biologic DMARDs: 1 year results of the ASSURE trial. Ann. Rheum. Dis. 64(Suppl. III [Op0012]), 60 (2005).
    • (2005) Ann. Rheum. Dis. , vol.64 , Issue.SUPPL. III , pp. 60
    • Weinblatt, M.E.1    Combe, B.2    White, A.3    Aranda, R.4    Becker, J.5    Keystone, E.6
  • 39
    • 18644370644 scopus 로고    scopus 로고
    • Rapid responses to anakinra in patients with refractory adult-onset Still's disease
    • Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 52(6), 1794-1803 (2005).
    • (2005) Arthritis Rheum. , vol.52 , Issue.6 , pp. 1794-1803
    • Fitzgerald, A.A.1    Leclercq, S.A.2    Yan, A.3    Homik, J.E.4    Dinarello, C.A.5
  • 40
    • 8444229328 scopus 로고    scopus 로고
    • Anakinra in mutation-negative NOMID/CINCA syndrome: Comment on the articles by Hawkins et al and Hoffman and Patel
    • Frenkel J, Wulffraat NM, Kuis W. Anakinra in mutation-negative NOMID/ CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel. Arthritis Rheum. 50(11), 3738-3739 (2004).
    • (2004) Arthritis Rheum. , vol.50 , Issue.11 , pp. 3738-3739
    • Frenkel, J.1    Wulffraat, N.M.2    Kuis, W.3
  • 41
    • 22144447157 scopus 로고    scopus 로고
    • The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide
    • Kallinich T, Hoffman HM, Roth J, Keitzer R. The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide. Scand. J. Rheumatol. 34(3), 246-249 (2005).
    • (2005) Scand. J. Rheumatol. , vol.34 , Issue.3 , pp. 246-249
    • Kallinich, T.1    Hoffman, H.M.2    Roth, J.3    Keitzer, R.4
  • 42
    • 0025274640 scopus 로고
    • Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
    • Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 33(3), 305-315 (1990).
    • (1990) Arthritis Rheum. , vol.33 , Issue.3 , pp. 305-315
    • Arend, W.P.1    Dayer, J.M.2
  • 43
    • 18244425295 scopus 로고    scopus 로고
    • The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis
    • Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 42(Suppl. 2), ii3-ii10 (2003)
    • (2003) Rheumatology (Oxford) , vol.42 , Issue.SUPPL. 2
    • Dayer, J.M.1
  • 44
    • 0025304539 scopus 로고
    • Rheumatoid arthritis. Pathophysiology and implications for therapy
    • Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. 322(18), 1277-1289 (1990).
    • (1990) N. Engl. J. Med. , vol.322 , Issue.18 , pp. 1277-1289
    • Harris Jr., E.D.1
  • 46
    • 0031786230 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with IL-1 inhibitors
    • Gabay C, Arend WP. Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Semin. Immunopathol. 20(1-2), 229-246 (1998).
    • (1998) Springer Semin. Immunopathol. , vol.20 , Issue.1-2 , pp. 229-246
    • Gabay, C.1    Arend, W.P.2
  • 47
    • 0025255530 scopus 로고
    • Quantitative analysis of cytokine gene expression in rheumatoid arthritis
    • Firestein GS, varo-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 144(9), 3347-3353 (1990).
    • (1990) J. Immunol. , vol.144 , Issue.9 , pp. 3347-3353
    • Firestein, G.S.1    Varo-Gracia, J.M.2    Maki, R.3
  • 48
    • 0026802287 scopus 로고
    • Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: Implications for the role of cytokines in cartilage destruction and repair
    • Chu CQ Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br. J. Rheumatol. 31(10), 653-661 (1992).
    • (1992) Br. J. Rheumatol. , vol.31 , Issue.10 , pp. 653-661
    • Chu, C.Q.1    Field, M.2    Allard, S.3    Abney, E.4    Feldmann, M.5    Maini, R.N.6
  • 49
    • 3442875303 scopus 로고    scopus 로고
    • Pathogenesis of bone and cartilage destruction in rheumatoid arthritis
    • Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 42(Suppl. 2), ii11-ii16 (2003).
    • (2003) Rheumatology (Oxford) , vol.42 , Issue.SUPPL. 2
    • Goldring, S.R.1
  • 50
    • 0029046142 scopus 로고
    • Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and 1L-1 β by site-directed mutagenesis. Identification of a single site in IL-1Ra and two sites in IL-1 β
    • Evans RJ, Bray J, Childs JD et al. Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and 1L-1 β by site-directed mutagenesis. Identification of a single site in IL-1Ra and two sites in IL-1 β. J. Biol. Chem. 270(19), 11477-11483 (1995).
    • (1995) J. Biol. Chem. , vol.270 , Issue.19 , pp. 11477-11483
    • Evans, R.J.1    Bray, J.2    Childs, J.D.3
  • 51
    • 0025713953 scopus 로고
    • Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor
    • Hannum CH, Wilcox CJ, Arend WP et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343(6256), 336-340 (1990).
    • (1990) Nature , vol.343 , Issue.6256 , pp. 336-340
    • Hannum, C.H.1    Wilcox, C.J.2    Arend, W.P.3
  • 53
    • 0025021471 scopus 로고
    • Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist
    • Eisenberg SP, Evans RJ, Arend WP et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343(6256), 341-346 (1990).
    • (1990) Nature , vol.343 , Issue.6256 , pp. 341-346
    • Eisenberg, S.P.1    Evans, R.J.2    Arend, W.P.3
  • 54
    • 34147139093 scopus 로고    scopus 로고
    • In: Thomson, Montvale, USA
    • Kineret. In: Physician's Desk Reference. Thomson, Montvale, USA, 594-596 (2006).
    • (2006) Physician's Desk Reference , pp. 594-596
    • Kineret1
  • 55
    • 0038434492 scopus 로고    scopus 로고
    • Pharmacokinetics of anakinra in subjects with different levels of renal function
    • Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin. Pharmacol. Ther. 74(1), 85-94 (2003).
    • (2003) Clin. Pharmacol. Ther. , vol.74 , Issue.1 , pp. 85-94
    • Yang, B.B.1    Baughman, S.2    Sullivan, J.T.3
  • 56
    • 17444394445 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
    • Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41(12), 2196-2204 (1998).
    • (1998) Arthritis Rheum. , vol.41 , Issue.12 , pp. 2196-2204
    • Bresnihan, B.1    Alvaro-Gracia, J.M.2    Cobby, M.3
  • 57
    • 0036190776 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
    • Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46(3), 614-624 (2002).
    • (2002) Arthritis Rheum. , vol.46 , Issue.3 , pp. 614-624
    • Cohen, S.1    Hurd, E.2    Cush, J.3
  • 58
    • 3442885115 scopus 로고    scopus 로고
    • A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate
    • Cohen SB, Moreland LW, Cush JJ et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63(9), 1062-1068 (2004).
    • (2004) Ann. Rheum. Dis. , vol.63 , Issue.9 , pp. 1062-1068
    • Cohen, S.B.1    Moreland, L.W.2    Cush, J.J.3
  • 59
    • 0037389680 scopus 로고    scopus 로고
    • Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial
    • Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 48(4), 927-934 (2003).
    • (2003) Arthritis Rheum. , vol.48 , Issue.4 , pp. 927-934
    • Fleischmann, R.M.1    Schechtman, J.2    Bennett, R.3
  • 61
    • 0029044362 scopus 로고
    • American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis
    • Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38(6), 727-735 (1995).
    • (1995) Arthritis Rheum. , vol.38 , Issue.6 , pp. 727-735
    • Felson, D.T.1    Anderson, J.J.2    Boers, M.3
  • 62
    • 0027412974 scopus 로고
    • Minimum important difference between patients with rheumatoid arthritis: The patient's perspective
    • Wells GA, Tugwell P, Kraag GR et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J. Rheumatol. 20, 557-560 (1993).
    • (1993) J. Rheumatol. , vol.20 , pp. 557-560
    • Wells, G.A.1    Tugwell, P.2    Kraag, G.R.3
  • 63
    • 0017658738 scopus 로고
    • Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films
    • Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol. Diagn. (Stockh.) 18(4), 481-491 (1977).
    • (1977) Acta Radiol. Diagn. (Stockh.) , vol.18 , Issue.4 , pp. 481-491
    • Larsen, A.1    Dale, K.2    Eek, M.3
  • 64
    • 0034083128 scopus 로고    scopus 로고
    • A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Radiologic. progression and correlation of Genant and Larsen scores
    • Jiang Y, Genant H, Watt I, Cobby M, Bresnihan B, Aitchison R. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43, 1001-1009 (2000).
    • (2000) Arthritis Rheum. , vol.43 , pp. 1001-1009
    • Jiang, Y.1    Genant, H.2    Watt, I.3    Cobby, M.4    Bresnihan, B.5    Aitchison, R.6
  • 65
    • 0036845130 scopus 로고    scopus 로고
    • Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist).in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial
    • Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist).in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46(11), 2838-2846 (2002).
    • (2002) Arthritis Rheum. , vol.46 , Issue.11 , pp. 2838-2846
    • Nuki, G.1    Bresnihan, B.2    Bear, M.B.3    McCabe, D.4
  • 66
    • 0042867068 scopus 로고    scopus 로고
    • Anakinra (Kineret®) inhibits the progression of radiographically measured joint destruction in rheumatoid arthritis
    • (Abstract)
    • Shergy W, Cohen S, Greenwald M et al. Anakinra (Kineret®) inhibits the progression of radiographically measured joint destruction in rheumatoid arthritis. Arthritis Rheum. 46(Suppl. 9), LB 10 (2002) (Abstract).
    • (2002) Arthritis Rheum. , vol.46 , Issue.SUPPL. 9
    • Shergy, W.1    Cohen, S.2    Greenwald, M.3
  • 67
    • 0037309790 scopus 로고    scopus 로고
    • Interleukin-1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis
    • Cohen SB, Woolley JM, Chan W. interleukin-1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J. Rheumatol. 30(2), 225-231 (2003).
    • (2003) J. Rheumatol. , vol.30 , Issue.2 , pp. 225-231
    • Cohen, S.B.1    Woolley, J.M.2    Chan, W.3
  • 68
    • 3442877556 scopus 로고    scopus 로고
    • Combination of TNFα soluble receptors (sR) with IL-1 and IL-17 sR is more effective to reduce in vitro inflammation response of synoviocytes stimulated with RA PBMC supernatants
    • (Abstract 127)
    • Chevrel G, Garnero P, Mirosses P. Combination of TNFα soluble receptors (sR) with IL-1 and IL-17 sR is more effective to reduce in vitro inflammation response of synoviocytes stimulated with RA PBMC supernatants. Arthritis Rheum. 43(Suppl. 9) (2000) (Abstract 127).
    • (2000) Arthritis Rheum. , vol.43 , Issue.SUPPL. 9
    • Chevrel, G.1    Garnero, P.2    Mirosses, P.3
  • 69
    • 3442892397 scopus 로고    scopus 로고
    • Combination therapy with anakinra and PEGylated soluble tumor necrosis factor type I (Pegsunercept).in rheumatoid arthritis (RA): Preliminary analysis of clinical, functional, synovial tissue and radiographic outcomes from a phase II, open-label, mode of action study
    • (Abstract 211)
    • Rooney T, Madigan A, Greenan L et al. Combination therapy with anakinra and PEGylated soluble tumor necrosis factor type I (Pegsunercept).in rheumatoid arthritis (RA): preliminary analysis of clinical, functional, synovial tissue and radiographic outcomes from a phase II, open-label, mode of action study. Arthritis Rheum. 48(Suppl. 9) (2003) (Abstract 211).
    • (2003) Arthritis Rheum. , vol.48 , Issue.SUPPL. 9
    • Rooney, T.1    Madigan, A.2    Greenan, L.3
  • 70
    • 16344364963 scopus 로고    scopus 로고
    • Refractory adult onset Still's disease successfully treated with anakinra
    • Vasques Godinho FM, Parreira Santos MJ, Canas da SJ. Refractory adult onset Still's disease successfully treated with anakinra. Ann. Rheum. Dis. 64(4), 647-648 (2005).
    • (2005) Ann. Rheum. Dis. , vol.64 , Issue.4 , pp. 647-648
    • Vasques Godinho, F.M.1    Parreira Santos, M.J.2    Canas da, S.J.3
  • 71
    • 5044223401 scopus 로고    scopus 로고
    • Effective use of the recombinant intereukin-1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis
    • Verbsky JW, White AJ. Effective use of the recombinant intereukin-1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 31(10), 2071-2075 (2004).
    • (2004) J. Rheumatol. , vol.31 , Issue.10 , pp. 2071-2075
    • Verbsky, J.W.1    White, A.J.2
  • 72
    • 18644385243 scopus 로고    scopus 로고
    • Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade
    • Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201(9), 1479-1486 (2005).
    • (2005) J. Exp. Med. , vol.201 , Issue.9 , pp. 1479-1486
    • Pascual, V.1    Allantaz, F.2    Arce, E.3    Punaro, M.4    Banchereau, J.5
  • 73
    • 0036899758 scopus 로고    scopus 로고
    • De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases
    • Aksentijevich I, Nowak M, Mallah M et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46(12),3340-3348 (2002).
    • (2002) Arthritis Rheum. , vol.46 , Issue.12 , pp. 3340-3348
    • Aksentijevich, I.1    Nowak, M.2    Mallah, M.3
  • 74
    • 0010464874 scopus 로고    scopus 로고
    • PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-κB and caspase-1-dependent cytokine processing
    • Wang L, Manji GA, Grenier JM et al. PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-κB and caspase-1-dependent cytokine processing. J. Biol. Chem. 277(33), 29874-29880 (2002).
    • (2002) J. Biol. Chem. , vol.277 , Issue.33 , pp. 29874-29880
    • Wang, L.1    Manji, G.A.2    Grenier, J.M.3
  • 75
    • 17244381937 scopus 로고    scopus 로고
    • Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease
    • Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 52(4), 1283-1286 (2005).
    • (2005) Arthritis Rheum. , vol.52 , Issue.4 , pp. 1283-1286
    • Lovell, D.J.1    Bowyer, S.L.2    Solinger, A.M.3
  • 76
    • 21244481363 scopus 로고    scopus 로고
    • Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome
    • Granel B, Serratrice J, Disdier P, Weiller PJ. Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology (Oxford) 44(5), 689-690 (2005).
    • (2005) Rheumatology (Oxford) , vol.44 , Issue.5 , pp. 689-690
    • Granel, B.1    Serratrice, J.2    Disdier, P.3    Weiller, P.J.4
  • 77
    • 4043104941 scopus 로고    scopus 로고
    • Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease
    • Hawkins PN, Bybee A, Aganna E, McDermott MF. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 50(8), 2708-2709 (2004).
    • (2004) Arthritis Rheum. , vol.50 , Issue.8 , pp. 2708-2709
    • Hawkins, P.N.1    Bybee, A.2    Aganna, E.3    McDermott, M.F.4
  • 78
    • 1042290321 scopus 로고    scopus 로고
    • Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra
    • Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50(2), 607-612 (2004).
    • (2004) Arthritis Rheum. , vol.50 , Issue.2 , pp. 607-612
    • Hawkins, P.N.1    Lachmann, H.J.2    Aganna, E.3    McDermott, M.F.4
  • 79
    • 4344643654 scopus 로고    scopus 로고
    • IL-1RA in refractory systemic lupus erythematosus
    • Moosig F, Zeuner R, Renk C, Schroder JO. IL-1RA in refractory systemic lupus erythematosus. Lupus 13(8), 605-606 (2004).
    • (2004) Lupus , vol.13 , Issue.8 , pp. 605-606
    • Moosig, F.1    Zeuner, R.2    Renk, C.3    Schroder, J.O.4
  • 80
    • 16344374294 scopus 로고    scopus 로고
    • Preliminary results of safety and efficacy of the interleukin-1 receptor antagonist anakinra in patients with severe lupus arthritis
    • Ostendorf B, Iking-Konert C, Kutz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin-1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann. Rheum. Dis. 64(4), 630-633 (2005).
    • (2005) Ann. Rheum. Dis. , vol.64 , Issue.4 , pp. 630-633
    • Ostendorf, B.1    Iking-Konert, C.2    Kutz, K.3    Jung, G.4    Sander, O.5    Schneider, M.6
  • 81
    • 4344699365 scopus 로고    scopus 로고
    • Efficacy of anakinra in active ankylosing spondylitis: A clinical and magnetic resonance imaging study
    • Tan AL, Matzo-Ortega H, O'Connor P, Fraser A, Emery P, McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann. Rheum. Dis. 63(9), 1041-1045 (2004).
    • (2004) Ann. Rheum. Dis. , vol.63 , Issue.9 , pp. 1041-1045
    • Tan, A.L.1    Matzo-Ortega, H.2    O'Connor, P.3    Fraser, A.4    Emery, P.5    McGonagle, D.6
  • 82
    • 0028579768 scopus 로고
    • A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index
    • Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J. Rheumatol. 21(12), 2281-2285 (1994).
    • (1994) J. Rheumatol. , vol.21 , Issue.12 , pp. 2281-2285
    • Calin, A.1    Garrett, S.2    Whitelock, H.3
  • 83
    • 0028575453 scopus 로고
    • A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index
    • Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J. Rheumatol. 21(12), 2286-2291 (1994).
    • (1994) J. Rheumatol. , vol.21 , Issue.12 , pp. 2286-2291
    • Garrett, S.1    Jenkinson, T.2    Kennedy, L.G.3    Whitelock, H.4    Gaisford, P.5    Calin, A.6
  • 84
    • 13244279795 scopus 로고    scopus 로고
    • Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
    • Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann. Rheum. Dis. 64(2), 296-298 (2005).
    • (2005) Ann. Rheum. Dis. , vol.64 , Issue.2 , pp. 296-298
    • Haibel, H.1    Rudwaleit, M.2    Listing, J.3    Sieper, J.4
  • 86
    • 0034888069 scopus 로고    scopus 로고
    • Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis
    • Anderson JJ, Baron G, Van Der HD, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 44(8), 1876-1886 (2001).
    • (2001) Arthritis Rheum. , vol.44 , Issue.8 , pp. 1876-1886
    • Anderson, J.J.1    Baron, G.2    Van Der, H.D.3    Felson, D.T.4    Dougados, M.5
  • 87
    • 2642550601 scopus 로고    scopus 로고
    • Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial
    • Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J. Rheumatol. 31(6), 1103-1111 (2004).
    • (2004) J. Rheumatol. , vol.31 , Issue.6 , pp. 1103-1111
    • Bresnihan, B.1    Newmark, R.2    Robbins, S.3    Genant, H.K.4
  • 88
    • 2642576804 scopus 로고    scopus 로고
    • The safety of anakinra in high-risk patients with active rheumatoid arthritis: Six-month observations of patients with comorbid conditions
    • Schiff MH, DiVittorio G, Tesser J et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum. 50(6), 1752-1760 (2004).
    • (2004) Arthritis Rheum. , vol.50 , Issue.6 , pp. 1752-1760
    • Schiff, M.H.1    DiVittorio, G.2    Tesser, J.3
  • 89
    • 1842425913 scopus 로고    scopus 로고
    • Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis
    • Tesser J, Fleischmann R, Dore R et al. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis. J. Rheumatol. 31(4), 649-654 (2004).
    • (2004) J. Rheumatol. , vol.31 , Issue.4 , pp. 649-654
    • Tesser, J.1    Fleischmann, R.2    Dore, R.3
  • 90
    • 33746578466 scopus 로고    scopus 로고
    • Safety of extended treatment with anakinra in patients with rheumatoid arthritis
    • (Epub ahead of print)
    • Fleischmann RM, Tesser J, Schiff M et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2006) (Epub ahead of print).
    • (2006) Ann. Rheum. Dis.
    • Fleischmann, R.M.1    Tesser, J.2    Schiff, M.3
  • 91
    • 33748508698 scopus 로고    scopus 로고
    • Surveillance, Epidemiology, and End Results (SEER)
    • National Cancer Institute. Program Public-Use Data (1973-1999). [11 Registries, 1992-1999]. DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission 2002
    • National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER). Program Public-Use Data (1973-1999).[11 Registries, 1992-1999]. DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission 2002 (2006).
    • (2006)
  • 92
    • 1542313935 scopus 로고    scopus 로고
    • Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α blockade
    • Buch MH, Bingham SJ, Seto Y et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α blockade. Arthritis Rheum. 50(3), 725-728 (2004).
    • (2004) Arthritis Rheum. , vol.50 , Issue.3 , pp. 725-728
    • Buch, M.H.1    Bingham, S.J.2    Seto, Y.3
  • 93
    • 4444268519 scopus 로고    scopus 로고
    • Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: Comment on the article by Buch et al
    • Saxne T, Larsson L, Geborek P. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al. Arthritis Rheum. 50(9), 3049-3050 (2004).
    • (2004) Arthritis Rheum. , vol.50 , Issue.9 , pp. 3049-3050
    • Saxne, T.1    Larsson, L.2    Geborek, P.3
  • 94
    • 33645890587 scopus 로고    scopus 로고
    • The use of anakinra in juvenile arthritis
    • Reiff A. The use of anakinra in juvenile arthritis. Curr. Rheumatol. Rep. 7(6), 434-440 (2005).
    • (2005) Curr. Rheumatol. Rep. , vol.7 , Issue.6 , pp. 434-440
    • Reiff, A.1
  • 96
    • 0036735247 scopus 로고    scopus 로고
    • Examining the efficacy of biologic therapy: Are there real differences?
    • Fleischmann RM. Examining the efficacy of biologic therapy: are there real differences? J. Rheumatol. 65, 27-32 (2002).
    • (2002) J. Rheumatol. , vol.65 , pp. 27-32
    • Fleischmann, R.M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.